KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Interest & Investment Income: 2009-2016

Historic Interest & Investment Income for Halozyme Therapeutics (HALO) over the last 7 years, with Dec 2016 value amounting to $1.3 million.

  • Halozyme Therapeutics' Interest & Investment Income was N/A to $11,346 in Q4 2009 from the same period last year, while for Dec 2009 it was $97,737, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2016, which is 214.22% up from last year.
  • As of FY2016, Halozyme Therapeutics' Interest & Investment Income stood at $1.3 million, which was up 214.22% from $422,000 recorded in FY2015.
  • Halozyme Therapeutics' Interest & Investment Income's 5-year high stood at $1.3 million during FY2016, with a 5-year trough of $73,000 in FY2012.
  • Its 3-year average for Interest & Investment Income is $663,333, with a median of $422,000 in 2015.
  • Data for Halozyme Therapeutics' Interest & Investment Income shows a peak YoY spiked of 214.22% (in 2016) over the last 5 years.
  • Halozyme Therapeutics' Interest & Investment Income (Yearly) stood at $73,000 in 2012, then surged by 213.70% to $229,000 in 2013, then increased by 5.68% to $242,000 in 2014, then soared by 74.38% to $422,000 in 2015, then skyrocketed by 214.22% to $1.3 million in 2016.